What records are connected here?
- Evidence lanes
- 1
- Source years
- 3
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
In clinical trials2,3Evidence: Large human trialsMetabolic and weight
Cotadutide is a synthetic peptide that activates both the GLP-1 and glucagon receptors, recorded in FDA’s substance registry.2,3 In a randomized Phase 2b trial of 834 adults with type 2 diabetes and overweight or obesity, it lowered blood sugar (HbA1c) and body weight more than placebo over 54 weeks; nausea and vomiting were its most common side effects.3 No FDA approval is reported in the sources reviewed here, and cotadutide is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.2,6
| What it is | A synthetic dual GLP-1 and glucagon receptor agonist peptide, recorded as cotadutide in FDA’s substance registry.2,3 |
|---|---|
| FDA status | Not FDA-approved. None of the sources reviewed here reports an approval of cotadutide.2,3 |
| Human evidence | A randomized Phase 2b trial in 834 adults with type 2 diabetes and overweight or obesity, published in 2021.3 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Cotadutide is a synthetic peptide recorded in FDA’s substance registry. The 2021 trial authors describe it as a dual GLP-1 and glucagon receptor agonist under development for liver disease and for kidney disease with type 2 diabetes.2,3
It acts on two hormone receptors, those for GLP-1 and for glucagon. The trial authors studied whether this combination improves blood sugar, weight and liver measures.3
The 2021 Phase 2b trial randomized 834 adults with type 2 diabetes not controlled by metformin to one of three strengths of cotadutide, placebo or open-label liraglutide, and continued treatment for 54 weeks.3
Cotadutide lowered HbA1c and body weight significantly more than placebo at 14 and 54 weeks. The highest strength also improved liver enzymes and liver fibrosis scores, which liraglutide did not.3
Nausea (35%) and vomiting (17%) were the most common adverse events with cotadutide, and they decreased over time.3
ClinicalTrials.gov lists a Phase 2 trial in non-cirrhotic steatohepatitis with fibrosis (NCT05364931) as completed in its September 3, 2025 record.1
Evidence-strength label: Large randomized human trials. How this label is assigned
None of the sources reviewed here reports an approval of cotadutide by FDA.2,3
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list cotadutide.4
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Cotadutide is not among them.5,6
Whether its liver effects translate into real benefit for liver disease: the 2021 trial measured liver biomarkers and scores in an exploratory analysis, not liver outcomes.3
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Cotadutide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Cotadutide are a bounded selection, not every registration or paper about Cotadutide. For the years before Cotadutide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Cotadutide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Cotadutide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
Not FDA-approved; studied in clinical trials. A randomized Phase 2b trial of 834 adults found lower blood sugar and weight than placebo over 54 weeks. Cotadutide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
Not FDA-approved; studied in clinical trials. A randomized Phase 2b trial of 834 adults found lower blood sugar and weight than placebo over 54 weeks. Cotadutide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date September 3, 2025
ClinicalTrials.gov record NCT05364931↗Added to PeptideScanner November 16, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT05364931↗Source date September 3, 2025Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT03625778↗Source date August 23, 2021Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT04208620↗Source date July 31, 2020PeptideScanner currently has no selected PubMed literature metadata records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
3 of 3 selected trial records include at least one phase value; 3 of 3 include a status value in the retained structured contract.
0 of 0 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT03625778 at 2026-11-16T01:47:38.899Z. Its registry update date was 2021-08-23, and PeptideScanner's reviewed identity mapping was cotadutide.
PeptideScanner retained ClinicalTrials.gov record NCT04208620 at 2026-11-16T01:47:38.899Z. Its registry update date was 2020-07-31, and PeptideScanner's reviewed identity mapping was cotadutide.
PeptideScanner retained ClinicalTrials.gov record NCT05364931 at 2026-11-16T01:47:38.899Z. Its registry update date was 2025-09-03, and PeptideScanner's reviewed identity mapping was cotadutide.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Selected records span July 31, 2020 to September 3, 2025. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05364931 at 2026-11-16T01:47:38.899Z. Its registry update date was 2025-09-03, and PeptideScanner's reviewed identity mapping was cotadutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03625778 at 2026-11-16T01:47:38.899Z. Its registry update date was 2021-08-23, and PeptideScanner's reviewed identity mapping was cotadutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04208620 at 2026-11-16T01:47:38.899Z. Its registry update date was 2020-07-31, and PeptideScanner's reviewed identity mapping was cotadutide.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
ClinicalTrials.gov · Official source · Source checked November 16, 2026
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
Diabetes Care · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026